In mice with asthma, PFR-CK, which also inhibits plasma kallikrein, factor XIIa (58) and granzyme A (59), was recently assessed (intraperitoneally every second day), displaying decreased airway eosinophil infiltration, reduced goblet cell hyperplasia, and improved lung function (15). This evidence concerns the gene GZMA and asthma.